NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
Back to search
Official data from USPTO
DRUG2DRUGS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
12/24/2024
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
08/23/2023
Registration date
12/24/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
12/24/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
03
Owner location
Minato-ku, Tokyo, JP
Examiner
HUSSAIN, TASNEEM
Law office
M90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of The stylized wording "DRUG2DRUGS" with "DRUG2" in black and "DRUGS" in green.
Holders and representatives
Holders
F. C. (pessoa física)
Representatives
Suzanne M. Hengl BAKER BOTTS L.L.P.
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical additives for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in scientific and biotechnological research and development
Class 5
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
Class 42
Development of pharmaceutical preparations and medicines; Consulting services in the fields of biotechnologypharmaceutical research and developmentlaboratory testingdiagnosticspharmacogenetics; Testing of pharmaceuticals; designdevelopment and research of chemicalspharmaceuticals and chemical compounds; consultancy and information services relating to designdevelopment and research of chemicalspharmaceuticals and chemical compounds; analysistesting and inspection of chemicalspharmaceuticals and chemical compounds; consultancy and information services relating to analysistesting and inspection of chemicalspharmaceuticals and chemical compounds; pharmaceutical drug development services; Technical research in the field of pharmaceutical studies; research on the subject of pharmaceuticals; pharmaceutical research services; consulting services in the field of pharmaceutical research; testinginspection or research of pharmaceuticals; pharmaceutical research and development; research of molecule design; consultancy and information services relating to research of molecule design; scientific research and testing surveys in the nature of research on the subject of pharmaceuticalspharmaceutical research and development and pharmaceutical drug development services; providing computer programsproviding on-line non-downloadable software for designdevelopment and research of compounds which are a source of pharmaceuticals in the field of development of new drugs; designing of machinesapparatusinstruments or systems composed of such machinesapparatus and instruments; rental of laboratory apparatus and instruments
Class 44
Providing medical information relating to diagnosticprevention and healing property of medicines; providing medical information relating to pharmaceuticals and compounds which is a source of pharmaceuticals; providing health information; dietary and nutritional guidance; rental of medical machines and apparatus; pharmaceutical compounding services
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/22/2024
PUBO
PUBLISHED FOR OPPOSITION
10/22/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/08/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/08/2024
ALIE
ASSIGNED TO LIE
09/08/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
04/11/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/06/2024
GNSL
LETTER OF SUSPENSION E-MAILED
03/06/2024
CNSL
SUSPENSION LETTER WRITTEN
03/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/15/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/15/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/15/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/20/2023
GNRT
NON-FINAL ACTION E-MAILED
12/20/2023
CNRT
NON-FINAL ACTION WRITTEN
12/20/2023
DOCK
ASSIGNED TO EXAMINER
12/18/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/23/2023
NWAP
NEW APPLICATION ENTERED
08/26/2023
Continuous trademark protection
Get notified about every new filing that threatens DRUG2DRUGS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.